AstraZeneca pauses AZD1222 Covid-19 vaccine trials after unexpected illness
AZD1222, which is currently in phase 3 trials, has been seen as one of the most promising vaccine candidates across the world that is likely to be approved
Johnson & Johnson has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) for the approval of nipocalimab, aimed at treating individuals with generalied myasthenia gravis (gMG).
The term “orphan drugs” refers to pharmaceutical products developed for the prevention, diagnosis, and treatment of rare diseases or conditions. In the United States, an orphan disease is
The post hoc analysis from the pivotal Phase III IRIDIUM study—presented virtually at the European Respiratory Society (ERS) International Congress 2020— also showed the safety profile for high-dose